Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Breast Cancer
Interventions
DRUG

Liposomal Doxorubicin

"Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"

Trial Locations (19)

28041

Hospital Universitario 12 de Octubre, Madrid

Unknown

Hospital Clínic de Barcelona, Barcelona

Hospital Universitario Vall d´Hebron, Barcelona

Complejo Hospitalario San Pedro de Alcántara, Cáceres

Hospital Universitari Arnau de Vilanova de Lleida, Lleida

Centro Integral Oncológico Clara Campal, Madrid

Hospital Universitario Clínico San Carlos, Madrid

Hospital Universitario Puerta de Hierro de Majadahonda, Madrid

MD Anderson Cancer Center Madrid, Madrid

Hospital Universitario Virgen de la Arrixaca, Murcia

Hospital Son Llàtzer, Palma de Mallorca

Hospital Universitari Son Espases, Palma de Mallorca

Hospital Sant Joan de Reus, Reus

Hospital Sagrado Corazón USP, Seville

Hospital Universitario Virgen del Rocío, Seville

Hospital Virgen de la Macarena, Seville

Fundación Instituto Valenciano de Oncología, Valencia

Hospital Arnau de Vilanova de Valencia, Valencia

Hospital Universitario Lozano Blesa, Zaragoza

All Listed Sponsors
lead

SOLTI Breast Cancer Research Group

OTHER

NCT01669239 - Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | Biotech Hunter | Biotech Hunter